HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of HMG-CoA reductase inhibitors (statins) compared with placebo for schizophrenia in adults.
Authors
- Yasushi Tsujimoto (ORCID: https://orcid.org/0000-0002-7214-5589)
- Yuki Kataoka (ORCID: https://orcid.org/0000-0001-7982-5213)
- Saehyeon Kim (ORCID: https://orcid.org/0000-0003-4028-3837)
- Masahiro Banno (ORCID: https://orcid.org/0000-0002-2539-1031)
- Yusuke Saishoji (ORCID: https://orcid.org/0000-0001-7163-8229)
- Kunihiro Kohmura
Institutions
- SUNY Upstate Medical University (US)
- Kyoto University (JP)
- Uji Hospital (JP)
- Scientific Research WorkS Peer Support Group
- Kyoto Min-iren Asukai Hospital
Publication Details
- Journal
- Cochrane Database of Systematic Reviews
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1002/14651858.cd014565
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00